Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9199 USD | -0.49% | -9.81% | -34.29% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
Business Summary
Number of employees: 233
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Microbiome Therapeutics
100.0
%
| 7 | 100.0 % | 126 | 100.0 % | +1,672.24% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 7 | 100.0 % | 126 | 100.0 % | +1,672.24% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eric Shaff
CEO | Chief Executive Officer | 48 | 14-10-31 |
David Ege
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-10-21 |
Chief Tech/Sci/R&D Officer | - | 15-04-30 | |
Kelly M. Brady
CTO | Chief Tech/Sci/R&D Officer | - | 18-05-31 |
Marcus Chapman
COO | Chief Operating Officer | 53 | 15-02-28 |
Lisa von Moltke
CTO | Chief Tech/Sci/R&D Officer | 65 | 20-02-29 |
Barbara McGovern
CTO | Chief Tech/Sci/R&D Officer | - | 15-03-31 |
Matthew Henn
CTO | Chief Tech/Sci/R&D Officer | 49 | 12-05-31 |
Carlo Tanzi
IRC | Investor Relations Contact | - | 15-09-30 |
Teresa Young
PRN | Corporate Officer/Principal | 57 | 20-06-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 78 | 15-03-31 |
Director/Board Member | 68 | 23-01-03 | |
Richard Kender
BRD | Director/Board Member | 68 | 14-10-05 |
Kurt Graves
BRD | Director/Board Member | 56 | 15-10-31 |
Paul Biondi
BRD | Director/Board Member | 54 | 20-03-19 |
Eric Shaff
CEO | Chief Executive Officer | 48 | 14-10-31 |
Willard Dere
BRD | Director/Board Member | 70 | 17-07-10 |
Stephen Berenson
CHM | Chairman | 63 | 19-08-04 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 151,447,763 | 142,822,322 ( 94.30 %) | 0 | 94.30 % |
Company contact information
Seres Therapeutics, Inc.
200 Sidney Street 4th floor
02139, Cambridge
+617 945 9626
http://www.serestherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.29% | 139M | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.47% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- MCRB Stock
- Company Seres Therapeutics, Inc.